Home· Settings· Breaking · FrontPage · Extended · Editorial · Activism · News

Prayer  PrayerRequest  SCOTUS  ProLife  BangList  Aliens  HomosexualAgenda  GlobalWarming  Corruption  Taxes  Congress  Fraud  MediaBias  GovtAbuse  Tyranny  Obama  Biden  Elections  POLLS  Debates  TRUMP  TalkRadio  FreeperBookClub  HTMLSandbox  FReeperEd  FReepathon  CopyrightList  Copyright/DMCA Notice 

Monthly Donors · Dollar-a-Day Donors · 300 Club Donors

Click the Donate button to donate by credit card to FR:

or by or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Free Republic 4th Qtr 2024 Fundraising Target: $81,000 Receipts & Pledges to-date: $14,445
17%  
Woo hoo!! And we're now over 17%!! Thank you all very much!! God bless.

Keyword: elevidys

Brevity: Headers | « Text »
  • Top FDA official Peter Marks overruled staff, review team to approve Sarepta gene therapy

    06/22/2024 12:18:08 PM PDT · by george76 · 11 replies
    STAT ^ | June 20, 2024 | Jason Mast and Matthew Herper
    For a third time, Sarepta Therapeutics has convinced a top Food and Drug Administration official to overrule the prevailing view of their staff and approve a drug for Duchenne muscular dystrophy. On Thursday evening, the FDA announced it expanded the approval of Elevidys, Sarepta’s Duchenne gene therapy, to cover nearly all patients, regardless of age or wheelchair status, despite the fact that the drug failed a large, Phase 3 trial last year. That decision, documents concurrently released by the agency show, was made almost exclusively by Peter Marks, the agency’s director of the Center for Biologics Evaluation and Research. He...